MANKIND Mankind Pharma Q1 FY27 results (Apr–Jun 2026) and concall
Mankind Pharma delivered a strong Q1 FY27, marked by robust revenue growth, significant margin expansion, and healthy profit increase. Performance was driven by strong momentum in chronic and international segments, alongside recovery in the acute portfolio. The company maintained disciplined capital allocation, reducing net debt, while strategically navigating market dynamics and new product launches.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 12.9%, net profit up 29.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 +12% | 3,443 +12% | 4,031 +13% |
| EBITDA | 816 | 683 | 847 | 921 | 919 +13% | 930 +36% | 1,056 +25% |
| Net profit | 385 | 425 | 445 | 520 | 414 +8% | 559 +32% | 574 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
